Wolfe Research initiated coverage of Spyre Therapeutics (SYRE) with an Outperform rating and $27 price target The company is an early stage biotech with Phase 1 readouts in 2025, offering a “very high ceiling potential” in ulcerative colitis and possibly Crohn’s disease, the analyst tells investors in a research note. With three shots on goal through three different combos, at least one of Spyre’s combos is expected to be taken forward, Wolfe adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYRE:
- Spyre Therapeutics Faces Compliance Hurdles After Transition from Smaller Reporting Company Status
- Buy Rating for Spyre Therapeutics: Promising Pipeline and Strategic Advancements Drive Growth Potential
- Buy Rating for Spyre Therapeutics Driven by Promising Drug Development and Strong Financial Position
- Spyre Therapeutics Reports Strong Progress and Financial Stability
- Spyre Therapeutics files $500M mixed securities shelf